Thank you for your interest in this edition of Medicom’s Conference Report covering the annual European Society of Cardiology Congress 2022 in beautiful Barcelona. This year’s meeting was rich with new scientific statements and guidelines as well as cutting edge science.
In the following pages you can read about new Society recommendations with regards to management of patients with ventricular tachycardia and sudden cardiac death prevention, pulmonary hypertension, and cardiovascular management of patients around non-cardiac surgery. Of great interest is the first statement on cardio-oncology, a complex and critical area of clinical need for cardiovascular clinicians. In addition, you will find new original research and late breaking science in heart failure, anticoagulation, prevention, chronic coronary syndromes, and artificial intelligence and digital health.
As always, our summaries are written independently and are peer-reviewed for balance. We hope you find this edition informative, engaging, and balanced and thank you again for your readership.
Marc P. Bonaca MD MPH
Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.
Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training, he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.
Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.
Conflict of Interest Statement:
Grant support to BWH from AstraZeneca, MedImmune, Merck, Pfizer
Grant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi
« Old dogs, new tricks: Acetazolamide plus loop diuretics improves decongestion Next Article
Novel scoring tool for post-COVID syndrome aids clinicians and researchers »